📈 Markets & Finance
Live
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
Written by Prosper Junior Bakiny for The Motley Fool -> Revolution Medicines has a promising cancer drug in development. Even with this medicine's prospects, the stock's valuation looks too frothy.
Nasdaq News — 29 July 2026
Text:
17
0
0
Revolution Medicines has a promising cancer drug in development.
Even with this medicine's prospects, the stock's valuation looks too frothy.
Shares
Read Full Story at Nasdaq News → Sources
📈 Markets & Finance
Indian Shares Marginally Lower In Early Trade
📈 Markets & Finance
Asian Markets Trade Mostly Higher
📈 Markets & Finance
Little Movement Seen For Thai Stock Market
📈 Markets & Finance
Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business
📈 Markets & Finance
Trump finalizes new tariffs on dozens of countries
📈 Markets & Finance
Bargain Hunting May Boost South Korea Shares
